|
1
|
Ryu MH and Kang YK: ML17032 trial:
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as
first-line therapy in advanced gastric cancer. Expert Rev
Anticancer Ther. 9:1745–1751. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schinzari G, Cassano A, Orlandi A, Basso M
and Barone C: Targeted therapy in advanced gastric carcinoma: The
future is beginning. Curr Med Chem. 21:1026–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Watari J, Chen N, Amenta PS, Fukui H,
Oshima T, Tomita T, Miwa H, Lim KJ and Das KM: Helicobacter pylori
associated chronic gastritis, clinical syndromes, precancerous
lesions, and pathogenesis of gastric cancer development. World J
Gastroenterol. 20:5461–5473. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Olivero M, Dettori D, Arena S, Zecchin D,
Lantelme E and Di Renzo MF: The stress phenotype makes cancer cells
addicted to CDT2, a substrate receptor of the CRL4 ubiquitin
ligase. Oncotarget. 5:5992–6002. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marteijn JA, Lans H, Vermeulen W and
Hoeijmakers JH: Understanding nucleotide excision repair and its
roles in cancer and ageing. Nat Rev Mol Cell Biol. 15:465–481.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vaezi A, Wang X, Buch S, Gooding W, Wang
L, Seethala RR, Weaver DT, D'Andrea AD, Argiris A, Romkes M, et al:
XPF expression correlates with clinical outcome in squamous cell
carcinoma of the head and neck. Clin Cancer Res. 17:5513–5522.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gregg SQ, Robinson AR and Niedernhofer LJ:
Physiological consequences of defects in ERCC1-XPF DNA repair
endonuclease. DNA Repair (Amst). 10:781–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu L, Chang Y, Ye J and Kumar S: Abstract
1923: Distinct evolutionary and mutational patterns in oncogenes
and tumor suppressor genes. Cancer Res. 75:abs. 1923. 2015.doi:
10.1158/1538-7445.AM2015-1923.
|
|
9
|
Liu J, He C, Xing C and Yuan Y: Nucleotide
excision repair related gene polymorphisms and genetic
susceptibility, chemotherapeutic sensitivity and prognosis of
gastric cancer. Mutat Res. 765:11–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ying M, Deng XD, Yu F, Zhang W, Wang SX,
Liu Y and Liu H: Association of XPF, levels and genetic
polymorphism with susceptibility to ischemic stroke. J Mol
Neurosci. 59:1–9. 2016.PubMed/NCBI
|
|
11
|
Cheng HB, Xie C, Zhang RY, Hu SS, Wang Z
and Yue W: Xeroderma pigmentosum complementation group F
polymorphisms influence risk of glioma. Asian Pac J Cancer Prev.
14:4083–4087. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh VV, Dutta D, Ansari MA, Dutta S,
Chandran B and Longnecker R: Kaposi's sarcoma-associated
herpesvirus induces the ATM and H2AX DNA damage response early
during de novo infection of primary endothelial cells, which play
roles in latency establishment. J Virol. 88:2821–2834. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei ZH, Guo WH, Wu J, Suo WH and Fu GH: A
nonsense mutation in the Xeroderma pigmentosum complementation
group F (XPF) gene is associated with gastric carcinogenesis. Gene.
537:238–244. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Graf N, Ang WH, Zhu G, Myint M and Lippard
SJ: Role of endonucleases XPF and XPG in nucleotide excision repair
of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
Chembiochem. 12:1115–1123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsumoto S, Fischer ES, Yasuda T, Dohmae
N, Iwai S, Mori T, Nishi R, Yoshino K, Sakai W, Hanaoka F, et al:
Functional regulation of the DNA damage-recognition factor DDB2 by
ubiquitination and interaction with xeroderma pigmentosum group C
protein. Nucleic Acids Res. 43:1700–1713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Facista A, Nguyen H, Lewis C, Prasad AR,
Ramsey L, Zaitlin B, Nfonsam V, Krouse RS, Bernstein H, Payne CM,
et al: Deficient expression of DNA repair enzymes in early
progression to sporadic colon cancer. Genome Integr. 3:32012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang X, Tseng CC, Bernstein L and Wu AH:
Family history of cancer and gastroesophageal disorders and risk of
esophageal and gastric adenocarcinomas: A case-control study. BMC
Cancer. 14:602014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reddy KM, Chang JI, Shi JM and Wu BU: Risk
of gastric cancer among patients with intestinal metaplasia of the
stomach in a United States Integrated Healthcare System. Clin
Gastroenterol Hepatol. 14:1420–1425. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Caruso RA, Branca G, Fedele F, Parisi A,
Finocchiaro G, Ieni A and Rigoli L: Eosinophil-specific granules in
tumor cell cytoplasm: Unusual ultrastructural findings in a case of
diffuse-type gastric carcinoma. Ultrastruct Pathol. 39:226–230.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khaleghian M, Shakoori A, Razavi AE and
Azimi C: Relationship of amplification and expression of the C-MYC
gene with survival among gastric cancer patients. Asian Pac J
Cancer Prev. 16:7061–7069. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Zuo X, Lv X, Kong F, Xu W and Yang
S: Association of DNA repair gene polymorphisms with response to
chemotherapy and prognosis of gastric cancer in a Chinese
population. Tumour Biol. 35:7569–7574. 2014. View Article : Google Scholar : PubMed/NCBI
|
